Simplify 1: Momelotinib vs Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis

June 2-6, 2017; Chicago, Illinois
Momelotinib achieved noninferior spleen response vs rituximab, with inferior total symptom response rate.
Format: Microsoft PowerPoint (.ppt)
File Size: 674 KB
Released: June 9, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings